DDInter484 DDInter1435
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Dasatinib {u} (Compound) treats {v} (Disease) hematologic cancer
Dasatinib {u} (Compound) binds {v} (Gene) SRC
Dasatinib {u} (Compound) upregulates {v} (Gene) SATB1
Dasatinib {u} (Compound) downregulates {v} (Gene) EBNA1BP2
Dasatinib {u} (Compound) causes {v} (Side Effect) Body temperature increased
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Granisetron
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Dasatinib (Compound) treats hematologic cancer (Disease)
Dasatinib (Compound) binds SRC (Gene)
Dasatinib (Compound) upregulates SATB1 (Gene)
Dasatinib (Compound) downregulates EBNA1BP2 (Gene)
Dasatinib (Compound) causes Body temperature increased (Side Effect)
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Dasatinib may lead to a major life threatening interaction when taken with Halofantrine